CNS Therapeutic Compounds with Modular Substituents for Depression and Aggression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective treatments for central nervous system (CNS) diseases and disorders such as depression, schizophrenia, and aggressive behavior in patients with Alzheimer's disease and other disorders.
Innovation Solution
Development of specific compounds, including those of Formula I, Formula II, Formula III, and Formula IV, or their pharmaceutically acceptable salts, which can be administered to treat CNS diseases and disorders, with varying substituents and functional groups to enhance therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments for CNS diseases are used, then some therapeutic effect is achieved, but the effectiveness is insufficient for conditions like depression, schizophrenia, and aggressive behavior
Solution Approach 1:
The patent develops a series of compounds (Formula I, II, III, IV) with varying substituents and functional groups that can treat multiple CNS disorders including depression, schizophrenia, and aggressive behavior. The core molecular structure is maintained while modifying substituents to achieve broad-spectrum efficacy across different psychiatric conditions, making the treatment universally applicable to various CNS diseases.
Solution Approach 2:
The patent systematically varies chemical parameters of the compounds including substituent types (R1-R7), functional groups (Z, A, B), ring structures (D), and chain lengths (m, n) to optimize therapeutic effectiveness. By changing these molecular parameters, the compounds achieve enhanced binding affinity and efficacy for multiple CNS targets, resolving the insufficiency of existing treatments.
2Reliability
If compounds with multiple substituents and functional groups are developed to enhance therapeutic efficacy, then treatment effectiveness improves, but the complexity of compound structure increases
Solution Approach 1:
The patent divides the complex molecular structure into distinct segments: a core scaffold (Formula I-IV) and variable substituent regions (R1-R7, Z, A, B, D). This segmentation allows systematic optimization of each component independently - the core provides structural stability while substituents provide therapeutic specificity, managing overall molecular complexity through modular design.
Solution Approach 2:
The patent applies different functional groups and substituents at specific positions (R1-R7) of the molecular scaffold to achieve localized therapeutic effects. Each substituent position is optimized for its specific function (e.g., R6 for CNS penetration, R7 for receptor binding), allowing the molecule to address multiple pathological mechanisms simultaneously without requiring uniform complexity throughout the entire structure.
Data Source
AI summary
Disclosed herein are substituted compounds, salts, and pharmaceutical formulations thereof, for the treatment of a central nervous system disease or disorder.